ReviewRetrovirology2007
Identifying HIV-1 dual infections.
Review in Retrovirology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 97 citations in OpenAlex.
- Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor.AIDS research and human retroviruses · 2016Trial
- HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.PLoS pathogens · 2013Trial
- HIV superinfection reveals sequential reservoir reactivation and immune-driven rebound dynamics.Journal of virology · 2026Article
- Double trouble: how co- and superinfections shape viral dynamics and host responses.Journal of virology · 2026Review
- Bang-bang control optimization in infectious disease model with incorporating breakthrough and reinfection.Scientific reports · 2026Article
- HIV-1 genetic diversity and reverse transcriptase resistance mutations in Benin before dolutegravir era, West Africa.PloS one · 2026Article
- Large-scale evaluation of HIV-1 DNA drug resistance testing as a robust tool for clinical decision-making: A nationwide study in China.Journal of pharmaceutical analysis · 2026Article
- Broadly neutralizing antibody responses in a Chinese acute HIV-1 infection cohort of men who have sex with men.PLoS pathogens · 2026Article
- A graph homomorphism approach for unraveling histories of metastatic cancers and viral outbreaks under evolutionary constraints.Nature communications · 2025Article
- Model-based evaluation of the impact of a potential HIV cure on HIV transmission dynamics.Nature communications · 2025Article
- The origin and transmission of HIV-1 CRF80_0107 among two major first-tier cities in China.BMC infectious diseases · 2025Article
- The genetic architecture of HIV-1 virulence.Virus evolution · 2025Article
- Article
- Review
- Co-Infections and Superinfections between HIV-1 and Other Human Viruses at the Cellular Level.Pathogens (Basel, Switzerland) · 2024Review
- Genetic Variability of Bovine Leukemia Virus: Evidence of Dual Infection, Recombination and Quasi-Species.Pathogens (Basel, Switzerland) · 2024Article
- Global asymptotic stability, extinction and ergodic stationary distribution in a stochastic model for dual variants of SARS-CoV-2.Mathematics and computers in simulation · 2023Article
- Genomic evidence for divergent co-infections of co-circulating SARS-CoV-2 lineages.Computational and structural biotechnology journal · 2022Article
- Case report: change of dominant strain during dual SARS-CoV-2 infection.BMC infectious diseases · 2021Article
- Haploflow: strain-resolved de novo assembly of viral genomes.Genome biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transmission of human immunodeficiency virus (HIV) is no exception to the phenomenon that a second, productive infection with another strain of the same virus is feasible. Experiments with RNA viruses have suggested that both coinfections (simultaneous infection with two strains of a virus) and superinfections (second infection after a specific immune response to the first infecting strain has developed) can result in increased fitness of the viral population. Concerns about dual infections with HIV are increasing. First, the frequent detection of superinfections seems to indicate that it will be difficult to develop a prophylactic vaccine. Second, HIV-1 superinfections have been associated with accelerated disease progression, although this is not true for all persons. In fact, superinfections have even been detected in persons controlling their HIV infections without antiretroviral therapy. Third, dual infections can give rise to recombinant viruses, which are increasingly found in the HIV-1 epidemic. Recombinants could have increased fitness over the parental strains, as in vitro models suggest, and could exhibit increased pathogenicity. Multiple drug resistant (MDR) strains could recombine to produce a pan-resistant, transmittable virus. We will describe in this review what is presently known about super- and re-infection among ambient viral infections, as well as the first cases of HIV-1 superinfection, including HIV-1 triple infections. The clinical implications, the impact of the immune system, and the effect of anti-retroviral therapy will be covered, as will as the timing of HIV superinfection. The methods used to detect HIV-1 dual infections will be discussed in detail. To increase the likelihood of detecting a dual HIV-1 infection, pre-selection of patients can be done by serotyping, heteroduplex mobility assays (HMA), counting the degenerate base codes in the HIV-1 genotyping sequence, or surveying unexpected increases in the viral load during follow-up. The actual demonstration of dual infections involves a great deal of additional research to completely characterize the patient's viral quasispecies. The identification of a source partner would of course confirm the authenticity of the second infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.